Home » Stocks » SCPH

scPharmaceuticals Inc. (SCPH)

Stock Price: $5.84 USD -0.22 (-3.63%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 163.31M
Revenue (ttm) n/a
Net Income (ttm) -32.21M
Shares Out 24.57M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $5.84
Previous Close $6.06
Change ($) -0.22
Change (%) -3.63%
Day's Open 6.06
Day's Range 5.74 - 6.05
Day's Volume 50,318
52-Week Range 5.06 - 11.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional cli...

2 months ago - Benzinga

BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

2 months ago - GlobeNewsWire

BURLINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

2 months ago - GlobeNewsWire

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of scPharmaceuticals Inc. ("scPharmaceuticals" or the "Company") (NASDAQ: SCPH). uch investors are ad...

4 months ago - PRNewsWire

scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult pati...

4 months ago - Zacks Investment Research

Scpharmaceuticals Inc (NASDAQ: SCPH) shares were hurtling toward their late March lows Monday after a binary event panned out negatively for the biopharma. What Happened: Burlington, Massachusetts-based...

4 months ago - Benzinga

BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

5 months ago - GlobeNewsWire

Commercial ization preparedness activities continuing ahead of December 30 PDUFA date for FUROS C IX ® (furosemide injection) for subcutaneous administration

5 months ago - GlobeNewsWire

BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimiz...

5 months ago - GlobeNewsWire

scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

7 months ago - Zacks Investment Research

scPharmaceuticals has created proprietary formulations of widely used, generically available IV drugs that can be more easily administered subcutaneously.

10 months ago - Seeking Alpha

The pharmaceutical company priced a secondary offering to raise capital.

11 months ago - The Motley Fool

Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020

1 year ago - GlobeNewsWire

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an anti... [Read more...]

Industry
Biotechnology
IPO Date
Nov 17, 2017
CEO
John Tucker
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
SCPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is 12.33, which is an increase of 111.13% from the latest price.

Price Target
$12.33
(111.13% upside)
Analyst Consensus: Buy